Pembrolizumab for Recurrent platinum-resistant ovarian cancer | Recurrent platinum-resistant fallopian tube cancer | Recurrent platinum-resistant primary peritoneal cancer

Inclusion criteria

• {"criterion_text":"-Platinum resistant (platinum free interval 1-6 months from last platinum dose) ovarian, Fallopian tube or primary peritoneal cancer\n-CPS score>1\n-Be willing and able to provide written informed consent/assent for the trial\n-Be ≥ 18 years of age on day of signing informed consent\n-Have measurable disease or evaluable based on RECIST 1.1 (patients with only CA 125 increase without evidence of disease are not included)\n-Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen\n-Have a performance status of 0 or 1 on the ECOG Performance Scale\n-Demonstrate adequate organ function (as defined in Table 1 of the protocol), all screening labs should be performed within 10 days of treatment initiation"}

Exclusion criteria

• {"criterion_text":"-Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\n-Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n-Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n-Has an active infection requiring systemic therapy\n-Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n-Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n-Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n-Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\n-Patients should not be breast-feeding during treatment and for 120 days following the end of treatment\n-Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\n-Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)\n-Has received >2 previous CHT lines\n-Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. Has received a live vaccine within 30 days of planned start of study therapy\n-Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n-Has a known history of active TB (Bacillus Tuberculosis)\n-Hypersensitivity to pembrolizumab or any of its excipients\n-Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n-Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n-Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n-Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability"}

Primary endpoints

• {"endpoint_text":"-Overall survival (OS)","definition_or_measurement_approach":""}

Secondary endpoints

• {"endpoint_text":"-Toxicity\n-Response rate\n-Progression free survival (PFS)\n-Quality of Life","definition_or_measurement_approach":"Toxicity: assess safety and tolerability (as per secondary objective: 'To assess the safety and tolerability of patients receiving pembrolizumab').\nResponse rate: assessed by RECIST 1.1 criteria (as per secondary objective: 'To assess the response rate (RECIST 1.1 criteria) of patients receiving pembrolizumab').\nProgression free survival (PFS): assessed as time to progression or death (secondary objective: 'To assess progression free survival (PFS) of patients receiving pembrolizumab').\nQuality of Life: patient-reported outcomes using the disease-related symptoms – physical (DRS–P) subscale of the NCCN-FACT FACT-Ovarian Symptom Index 18 (FOSI-18) and Euro-Quality of Life 5D (EQ-5D) tool (as per secondary objective)."}

Other endpoints

• {"endpoint_text":"-Exploratory Objective: To investigate the relationship between different CPS score cut off and response to Pembrolizumab treatment utilizing newly obtained or archival FFPE tumor tissue.\n-Exploratory Objective: To investigate the relationship between lymphoid or myeloid-derived suppression cells (MDSC) or T-regulatory cells (T-refs) and response to Pembrolizumab treatment using archival FFPE tumor tissue and blood sampling","definition_or_measurement_approach":"First exploratory objective: assessment of CPS score cut-offs vs response using newly obtained or archival FFPE tumor tissue. Second exploratory objective: investigation of relationship between MDSC or T-regulatory cells and response using archival FFPE tumor tissue and blood sampling."}

Italy

Earliest CTIS Part Ii Submission Date

08-10-2024

Latest Decision Or Authorization Date

11-11-2024

Processing Time Days

34

Number Of Sites

11

Number Of Participants

100

Primary sponsor

Full Name

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Italy